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Abstract
The V3 loop of the HIV-1 Env protein is the primary determinant of viral coreceptor usage, whereas the V1V2 loop region is
thought to influence coreceptor binding and participate in shielding of neutralization-sensitive regions of the Env
glycoprotein gp120 from antibody responses. The functional properties and antigenicity of V1V2 are influenced by changes
in amino acid sequence, sequence length and patterns of N-linked glycosylation. However, how these polymorphisms relate
to HIV pathogenesis is not fully understood. We examined 5185 HIV-1 gp120 nucleotide sequence fragments and clinical
data from 154 individuals (152 were infected with HIV-1 Subtype B). Sequences were aligned, translated, manually edited
and separated into V1V2, C2, V3, C3, V4, C4 and V5 subregions. V1-V5 and subregion lengths were calculated, and potential
N-linked glycosylation sites (PNLGS) counted. Loop lengths and PNLGS were examined as a function of time since infection,
CD4 count, viral load, and calendar year in cross-sectional and longitudinal analyses. V1V2 length and PNLGS increased
significantly through chronic infection before declining in late-stage infection. In cross-sectional analyses, V1V2 length also
increased by calendar year between 1984 and 2004 in subjects with early and mid-stage illness. Our observations suggest
that there is little selection for loop length at the time of transmission; following infection, HIV-1 adapts to host immune
responses through increased V1V2 length and/or addition of carbohydrate moieties at N-linked glycosylation sites. V1V2
shortening during early and late-stage infection may reflect ineffective host immunity. Transmission from donors with
chronic illness may have caused the modest increase in V1V2 length observed during the course of the pandemic.
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Introduction
The gp120 portion of the HIV-1 envelope protein (Env)
mediates attachment prior to fusion with the host cell membrane
during target cell infection. gp120 has five hypervariable regions
(V1–V5) bounded by cysteine residues and separated by four
relatively ‘‘constant’’ regions (C1–C4) [1–3]. Gp120 is notable for
its sequence variation, which may arise through recombination
and point mutation, as well as by insertion and deletion of one or
more nucleotides. Insertion and deletion events (indels) occur
throughout env but are maintained through positive selection
particularly within the hypervariable loops, which thereby may
acquire significant length variation [4], The third hypervariable
region is known to encode the primary determinants of coreceptor
usage specificity [5–7], as well as epitopes recognized by humoral
[8,9] and cellular [10,11] immune responses. V3 loop sequence
variation has been extensively studied, and correlated with
changes in host cell range, cytopathogenicity, and disease
progression [12–14].
The V1V2 region in particular is characterized by a high degree
of length polymorphism, sequence variation, and predicted N-
linked glycosylation sites (PNLGS) [15–20], each of which may
affect viral attachment, coreceptor usage and recognition by
neutralizing antibodies [20,21]. Comparison of structural models
of gp120 and gp120 bound to CD4 and a chemokine coreceptor
have yielded considerable insight into the functional roles played
by V1V2 and V3 during viral attachment [22,23]. In the unbound
gp120 conformation, the V2 loop partially obscures V3 and other
gp120 residues involved in coreceptor binding. Binding to CD4
induces conformational changes that expose the coreceptor
binding site on gp120, including residues from V1V2, V3 and
other regions [22,24].
Numerous studies have suggested that sequence variation in
V1V2 influences host cell range and/or syncytium-inducing (SI)
phenotype [25–31]. For example, Toohey demonstrated that
recombinant chimeric clones with a V1V2 region from macro-
phage-tropic HIV-1 strains replicated efficiently in macrophages,
whereas clones with the V1V2 region from lymphotropic strains
did not [31]. However, not all studies have been concordant on
the role of V1V2 in viral replication kinetics, cell range and
transmission [15–19,32]. For example, Pastore showed that
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mutations in V3 associated with a change in coreceptor usage
[33], and V2 polymorphisms have also been linked with restriction
to CCR5 coreceptor usage [16]. In contrast, Wang et al found no
relationship between SI phenotype and V1V2 sequence, length,
distribution of PNLGS or charge [32].
The V1V2 region also appears to be an important determinant
of sensitivity to neutralizing antibodies [34–38]. The V1V2 region
evolves under positive natural selection in vivo [4,39–41], and an
inverse relationship between V1–V4 length and neutralization
susceptibility has been demonstrated in subtypes A [20], B [34–38]
and C [42]. Tellingly, laboratory strains lacking V1V2 may still
replicate efficiently in vitro, but appear to be especially sensitive to
antibody neutralization [43,44]. Consistent with this observation,
viral strains with shorter and less glycosylated V1V4 regions have
been reported to preferentially replicate in subjects newly infected
with HIV-1 subtype C [45] (where presumably an effective
neutralizing antibody response has not had time to emerge), and
similar observations have been made concerning the V1V2 loop in
individuals recently infected by HIV-1 subtype A [19]. However,
we and others have not observed this effect in HIV-1 subtype B
[19,46,47].
Despite these reports, the relationship between V1V2 region
length polymorphism and disease progression remains unclear. In
two small longitudinal studies, elongation of V1 and V2 was noted
in long-term nonprogressors (LTNP), but not within individuals
progressing rapidly to AIDS [15–19]. In a third study, no clear
relationship between V1V2 length variation and disease progres-
sion was observed [48]. Lastly, some investigators postulate that
V1V2 length changes positively correlate with the pace of disease
progression [16,19], while others have suggested that V1V2 length
increase may be a correlate of delayed progression to AIDS [18].
Thus, our understanding of the role of the V1V2 loop in
influencing HIV pathogenesis remains incomplete and is chal-
lenged by several contradictory observations. To more fully
characterize HIV envelope subregion variability and to clarify the
associations between subregion length variation, glycosylation, and
disease progression, we have comprehensively examined length
and glycosylation of each gp120 subregion as a function of clinical
parameters in a large collection HIV-1 subtype B infected
individuals.
Methods
Ethics statement
This study was performed using publicly available data from the
Los Alamos database, and previously unpublished experimental
data obtained at the University of Washington. Unpublished data
were obtained and analyzed with written informed consent of
study participants, and approval by the University of Washington
Institutional Review Board.
Patient selection
We analyzed new and published HIV-1 envelope gene
sequences and associated clinical data from all available subjects
in the Seattle Primary Infection Cohort (PIC) [49], the Multicenter
AIDS Cohort Study (MACS) [50], and from the Los Alamos
National Laboratories HIV database (HIVDB) (http://www.hiv.
lanl.gov/content/hiv-db/mainpage.html) not meeting pre-speci-
fied exclusion criteria. Subjects were excluded from this study if
younger than 18 years of age or if there was any history of
antiretroviral therapy prior to sampling as determined by patient
report and clinical records (MACS, PIC) or as indicated in the
methods section of published reports (HIVDB), unless otherwise
noted. All subjects considered in the cross-sectional and longitu-
dinal analyses were infected with HIV-1 subtype B, except for two
subjects infected with HIV-1 subtype A who were included in
longitudinal analyses, but were excluded from cross-sectional
analyses. (Additional subtypes were considered in analyses of env
subregion length change during transmission, presented in Text
S1, Section 8). Clinical data retrieved included CD4 count, viral
load, time since infection, and treatment history. Sequence data
were only accepted if directly derived from plasma or PBMC
without an intervening step involving viral propagation in vitro.I n
some cases, individual authors were consulted to resolve clinical or
methodological ambiguities. Accession numbers for published
sequences are provided in Table S1. Gene sequence data used in
this study are available at http://mullinslab.microbiol.washington.
edu/publications/curlin_2010/.
Subject groups
Viral gene sequence data were considered in both cross-
sectional (Table 1) and longitudinal analyses (Table 2). The cross-
sectional dataset included only plasma and PBMC sequences
derived from individuals infected with subtype B (see results, and
Table 1). Sequences were triaged by author, database identifier
and associated clinical data to exclude duplicate entries. To assess
the role of stage of illness on loop length variation, subjects were
divided into four non-overlapping groups; group Cx1 subjects were
sampled within two months of the estimated time of infection.
Group Cx2 subjects were sampled between two months and three
years following infection. Group Cx3 subjects were sampled at times
.3 years post infection. Group Cx4 was comprised of all individuals
meeting 1993 CDC criteria for AIDS when sampling occurred
(generally CD4 count ,200/mm
3), regardless of time since
infection.
The longitudinal dataset was derived from 20 subjects infected
with subtype B and 2 individuals infected with subtype A, from the
PIC cohort and from previous reports [18,51–55], in whom data
were available from two or more timepoints (see results, and Table
2). All intra-individual longitudinal comparisons were made
between sequences obtained from the same compartment (e.g.,
plasma vs. plasma). Individuals partitioned into group L1 (N=15)
Author Summary
The HIV envelope gene (env) encodes viral surface proteins
(Env) that are vital to the basic processes used by the virus
to infect and cause disease in humans. Adaptations in env
determine which cells the virus can infect, and permit the
virus to avoid elimination by the immune system. Env is
one of the most variable genes known, and it can change
dramatically over time in a single individual. However, Env-
host cell interactions are complex and incompletely
understood, and changes in this viral protein during
infection have not yet been systematically described. We
examined a large number of env sequences from 154
individuals at various stages of HIV infection but who had
never received antiretroviral treatment. We found that the
env V1V2 region lengthens during chronic infection and
becomes more heavily glycosylated. However, these
changes partially reverse during late-stage illness, possibly
in response to a weakening host immune system. V1V2
lengths are also increasing over time in the epidemic at
large, possibly related to the epidemiology of HIV
transmission within the subtype B epidemic. These results
provide fundamental insights into the biology of HIV.
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Cross-sectional Data
Group Subjects Samples Sequences
V1V2 C2 V3 C3 V4 C4 V5
TOTAL 152 453 1922 1275 4407 3616 4406 4405 4407
MACS 27 227 682 682 2567 2568 2567 2569 2569
PIC 43 78 541 390 846 845 845 845 847
LANL 82 148 699 203 994 203 994 991 991
Sequences by category
PBMC 62 225 385 65 2193 1675 2193 2193 2193
Plasma 90 228 1537 1210 2214 1941 2213 2212 2214
Asia 11 16 176 0 0 0 0 0 0
North America 111 362 1585 1207 3725 3548 3724 3726 3728
South America 555 5 55 555
Western Europe 25 70 156 63 677 63 677 674 674
Stage 1 41 42 418 365 383 383 383 384 384
Stage 2 40 146 872 741 1540 1483 1539 1540 1542
Stage 3 22 156 220 94 1586 1029 1586 1583 1583
Stage 4 11 63 170 35 631 631 631 631 631
Unknown Stage 38 46 242 40 267 90 267 267 267
Number of subjects, samples, and available coding sequences by cohort, gene region, anatomical site, geographic location, and stage of illness.
doi:10.1371/journal.ppat.1001228.t001
Table 2. Distribution of subjects, samples and sequences in longitudinal analyses.
Longitudinal Data
Group Subjects Samples Sequences
V1V2 C2 V3 C3 V4 C4 V5
TOTAL 22 83 807 30 155 155 155 155 155
PIC 1 15 180 30 155 155 155 155 155
LANL 21 68 627 0 0 0 0 0 0
Sequences by category
Culture NA 1 33 0 0 0 0 0 0
Cervical Swab NA 7 37 0 0 0 0 0 0
PBMC N / A 4 3 3 9 7 00 00 0 0
Plasma N/A 32 340 30 155 155 155 155 155
Subtype A 22 6 1 7 2 00 00 0 0
Subtype B 20 57 635 30 155 155 155 155 155
Asia 491 0 2 00 00 0 0
East Africa 22 6 1 7 2 00 00 0 0
North America 12 40 440 30 155 155 155 155 155
Western Europe 489 300 00 0 0
Stage 1 N A 56 31 0 2 32 3 2 32 32 3
Stage 2 NA 12 140 10 111 111 111 111 111
Stage 3 NA 10 111 10 21 21 21 21 21
Stage 4 NA 9 86 0 0 0 0 0 0
Unknown Stage 10 47 407 0 0 0 0 0 0
Number of subjects, samples, and available coding sequences by cohort, gene region, anatomical site, HIV subtype, geographic location, and stage of illness.
doi:10.1371/journal.ppat.1001228.t002
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(median follow-up 3.25 years, range 1 to 20.8 years), whereas
subjects in group L2 (N=7) were reported to have an AIDS-
defining illness or peripheral CD4 count ,200/mm
3 between the
first and second samples (median follow-up 2.75 years, range 2 to 4
years).
Nucleic acid isolation, cloning and sequencing
Sequences from the PIC and MACS cohorts (Tables 1 & 2)
were obtained from plasma or PBMC by standard methods
[56,57], using safeguards to prevent contamination and template
resampling [58]. Briefly, PCR amplification was performed using
Taq polymerase (Bioline) with primers ED3 and BH2 [59] (first
round) followed by ED5 and DR7 (second round) [60]. PCR
products were cloned into a TA TOPO vector (Invitrogen) and
selected colonies sequenced under contract using Big Dye dye-
terminator protocols. Genbank accession numbers pending
submission.
Sequence analysis
Deduced amino acid sequences were aligned using ClustalW
[61] and divided into seven subregions; V1V2 (HXB2 nucleotide
positions 6615–6812), C2 (HXB2 6813-7109), V3 (HXB2 7110–
7217), C3 (HXB2 7218–7376), V4 (HXB2 7377–7478), C4
(HXB2 7479–7556), and V5 (HXB2 7557–7637). Alignments
were manually edited and subregion lengths were counted using
MacClade. PNLGS were counted using NetNGlyc.1 (http://www.
cbs.dtu.dk/services/NetNGlyc/). Coreceptor usage (CCR5 vs.
CXCR4 tropism) was predicted for all available subtype B V3
loop sequences, using the Position-Specific Substitution Method
(PSSM) [62], Geno2pheno [63] and two other machine learning
algorithms [64,65] (hereafter denoted PSSM, G2P, PGRC and
BMLC, respectively). For G2P coreceptor usage predictions, we
selected the standard 10% false positivity threshold, and PGRC
predictions were based on the support vector machine (SVR) user
option. Estimated time since infection was calculated for all data
entries. When time was reported as time since onset of symptoms
or time post seroconversion (SC), symptoms and seroconversion
were assumed to occur at 14 days and 42 days after infection,
respectively [66,67]. Date of seroconversion was assumed to occur
at the midpoint between most recent negative serological test and
first reported positive test, unless additional information was
available.
Statistical analysis
For cross-sectional analyses, univariate and multivariate regres-
sions were conducted assessing subregion lengths and number of
glycosylation sites as a function of time since infection, stage of
disease, CD4 count, HIV viral load, adjusting for sample source
(plasma vs. PBMC), and date of sampling (calendar year). In
regression analyses, to allow direct comparisons of the effect of
each variable on V1V2 length and/or glycosylation, we compared
b values (i.e., regression coefficients scaled such that each variable
is equivalent to having a mean value of 0 and a standard deviation
of 1). Generalized estimating equations (GEE) were utilized to
account for non-independence of data points [68–70], and an
exchangeable correlation structure was assumed. This method
adjusts for the correlation of multiple sequences nested within a
sample as well as multiple samples per patient. As an additional
means of verifying that analysis outcomes were not influenced by
data linkage, regression analyses were performed on replicate data
subsets reconstituted from the original data by random resam-
pling, including analyses on 100 data subsets each obtained by
using one randomly selected sequence from each individual (See
Text S1 section S2). To ensure that results were not unduly
influenced by outlying sequences with extremely short or long loop
lengths, analyses were repeated after excluding sequences
representing the shortest 5% and longest 5% of the V1V2 loops
in the dataset. For the longitudinal dataset, multivariate linear
regressions were conducted assessing V1V2 length and number of
glycosylation sites as a function of time since infection within a
person, and the mean rate of change per year was estimated.
Statistical analyses were performed using SAS version 9.1 (SAS
Institute, Cary, NC).
Results
Sequence data
We obtained 5185 partial length HIV-1 env gene sequences for
cross-sectional and longitudinal analysis by the methods described
above (Tables 1 & 2). Sequences were isolated from 475 samples
obtained from 154 individuals, including 27 from the MACS, 43
from the Seattle PIC and 84 from the HIVDB. Study subjects
resided in North America (N=116), Western Europe (N=25),
East Africa (N=2), and Asia (N=11), contributed a median of 14
sequences (range 1–287) and included persons in stages 1 (N=41),
2 (N=62), 3 (N=40), and 4 (N=27) of infection (note that some
subjects contributing to the longitudinal analysis were included at
more than one stage of infection). Sequences were derived from
plasma (N=2495), PBMC (N=2620) and other sites (N=70).
Sequences were of subtype B (N=5013) and subtype A (N=172).
All subtype A sequences and sequences derived from sites other
than blood were excluded from cross-sectional analyses, but were
considered as special cases under longitudinal analyses (sequence
data available at: *webaddress pending acceptance*).
Cross-sectional analyses
Variation in sequence length and glycosylation. The
V1V2, V4 and V5 hypervariable regions displayed heterogeneity
in lengths up to approximately 2-fold in the 152 individuals
examined. V1V2 was the most variable region, with loop lengths
ranging from 50 to 99 amino acids (mean=68), while V4 and V5
loop lengths ranged from 19 to 44 (mean=32), and 14 to 36
(mean=28) amino acids, respectively. In contrast, the V3 loop and
the C2, C3 and C4 regions showed relatively little length variation
(Figure 1). The subregions with the greatest number of potential
glycosylation sites were V1V2 (mean 6 sites, range 0–12), C2
(mean 5, range 3–8) and V4 (mean 5, range 1–7). V3, C3 and V5
were more modestly glycosylated (mean=1, 3, and 2, respectively,
with a maximum of 5 glycosylated sites), whereas C4 rarely
contained potential glycosylation sites (1 site was found in 8 of
4403 sequences).
Relationship between V1V2 loop length, sample features
and clinical factors – univariate analyses. (And see Text S1,
sections S1, S3, S6, and Figures S1, S2 and S12.) We examined
V1V2 loop lengths as a function of year of sampling and specimen
type (plasma vs. PBMC). In separate univariate GEE analyses,
V1V2 length increased with calendar year of sampling (b=1.62
increase in V1V2 length per year; p=0.003, Figure 2, lower panel)
and trended towards greater length in PBMC, though not
significantly (b=1.70 for PBMC compared to plasma; p=0.11).
We then examined individual subregion lengths as a function of
time since infection, clinical stage, CD4 counts, and HIV plasma
viral load. In separate GEE regression analyses, V1V2 length was
significantly correlated with time since infection (b=1.00 increase
in V1V2 length per year; p,0.001, Figure 2, upper panel) and
clinical stage, as subjects with stage 3 (b=6.36; p,0.001) and
stage 4 (b=3.30; p=0.02), but not stage 2 (b=0.80; p=0.4) had
HIV env Length Variation and Disease Progression
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1 infection (Figure 3 and S12). However, V1V2 length did not
significantly correlate with either CD4 stratum (,200, 200–500 or
.500 cells/ml) or plasma viral load.
Relationship between V1V2 loop length, sample features
and clinical factors – multivariate analyses (Table 3). To
further understand the interaction between significant variables,
we next performed multivariate analyses of V1V2 length vs. time
since infection, clinical stage, CD4 level, and HIV viral load after
adjusting for calendar year and type of sample. This analysis was
performed for all sequences in the dataset, as well as with plasma
sequences and PBMC sequences considered separately (Table 3).
Overall, V1V2 length was not significantly associated with time
since infection, CD4 level, or HIV viral load. However, among
sequences derived from plasma, V1V2 length was significantly
associated with increased time since infection (b=0.77 per year;
p,0.001). Conversely, among the PBMC sequences, V1V2 length
was associated with decreased CD4 counts (b=8.13 for CD4
counts between 200 and 500 and b=6.77 for CD4 counts less
than 200 compared to .500) although the association with the
lowest CD4 count group did not reach statistical significance
(p=0.09). Among subjects without AIDS (Stages 1 through 3),
V1V2 length was associated with time since infection (b=0.70
increase in V1V2 length per year; p,0.001), even after adjustment
for calendar year and type of sample (data not shown). Overall,
after adjusting for calendar year and sample type, V1V2 length
remained significantly associated with clinical stage, as subjects
with stage 3 (b=6.25; p,0.001) and stage 4 (b=3.54; p=0.02),
but not stage 2 (b=0.09; p=0.9) had significantly longer V1V2
lengths compared to subjects with stage 1 infection. However,
V1V2 lengths in subjects with clinical stage 4 were significantly
shorter than V1V2 lengths from subjects in stage 3 (p,0.001). The
findings of increased V1V2 length in stage 3 and 4 infection
compared to stage 1 and 2 were similarly noted both among
Figure 1. Schematic diagram of HIV-1 env subregions (center bar) and distribution of subregion loop lengths (surrounding bar
graphs). The center bar depicts the linear arrangement of subregions V1V2 through V5 within the HIV Env gp120 protein. The amino acid length
distribution of each subregion is shown in the linked bar graphs, including sequences in the cross-sectional dataset, the longitudinal dataset and the
transmission data described in Text S1. Length distributions in V1V2 and V4 data are shown by isolation site (PBMC = blue bars, plasma = red bars,
cervical cells = green bars, CSF = light gray bars, dendritic cells = orange bars, cell culture = dark gray bars, and cells from unknown anatomic
compartments represented by open bars), and by subtype (subtype B = blue bars, subtype A = red bars, subtype C = green bars, subtype G =
orange bars, untyped sequences = open bars). V5 sequences were all of subtype B. X-axis: sequence length (amino acids); Y-axis: number of
sequences.
doi:10.1371/journal.ppat.1001228.g001
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plasma associations did not reach statistical significance in all
cases. In order to assess the potential that the results regarding
clinical and viral factors associated with V1V2 length could be
driven by unusually short or long sequences, we repeated the
above analyses excluding the shortest and longest 5% of V1V2
lengths. Since model coefficients and p-values were similar in this
restricted analysis (Table S2), our findings do not appear to be
unduly influenced by a small number of outlying small or large
sequences (Also see Text S1, section S3 and Figure S6).
As an alternative means of accounting for the variable number
of sequences contributed by study subjects, the data was subjected
to a resampling analysis, in which each subject contributed a single
randomly selected sequence. This process was repeated 100 times,
Figure 3. Correlation between stage of illness and V1V2 length. Lengths are indicated in amino acids. Sequences from plasma are
represented by diamonds and sequences from PBMC are represented by circles. Overlapping data points appear as darker symbols. Quartiles and
median values are indicated by horizontal line segments. Stage 1, 2, and 3 subjects were sampled within two months, between two months and
three years, and at times .3 years post infection, respectively. Stage 4 subjects were comprised of all individuals meeting 1993 CDC criteria for AIDS
when sampling occurred, regardless of time since infection.
doi:10.1371/journal.ppat.1001228.g003
Figure 2. V1V2 length vs. time since infection (upper panel) and vs. year of sampling (lower panel). Lengths are indicated in amino acids.
Overlapping data points appear as darker symbols. Sequences from plasma are represented by diamonds and sequences from PBMC are represented
by circles. Regression coefficients and coefficients of determination are shown for univariate linear regression, for plasma (red line) and PBMC (blue
line).
doi:10.1371/journal.ppat.1001228.g002
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the observed relationship between V1V2 length and time since
infection, and year of sampling were not significantly biased due to
the inclusion of individuals with multiple sequences (See Text S1,
section S2 and Figure S5).
Relationship between V4 and V5 loop lengths and clinical
variables. (Also see Text S1, section S4 and Figure S7.) Despite
their high degree of length variability, V4 and V5 loop lengths did
not appear to vary significantly by time since infection in
univariate regression analyses. In separate analyses adjusting for
sample year and type, V4 length appeared somewhat increased in
those with stage 2 (b=1.22, p=0.02), stage 3 (b=0.98, p=0.09)
or stage 4 (b=1.11, p=0.10) compared to stage 1 infection. In
contrast, V5 length decreased with increasing time after infection
(b=20.07, p,0.001), was decreased in stage 4 (b=20.69,
p=0.01 compared to stage 1), and was decreased in those with
CD4 counts below 200 cells/ml (b=20.66, p=0.002) compared
to those with CD4 counts above 500 cells/ml.
Relationship between subregion glycosylation and
clinical variables. (And see Text S1 section S1, and Figures
S3, S4 and S8.) In separate univariate GEE analyses, the number
of PNLGS in V1V2 increased with calendar year of sampling
(b=0.06 increase per year; p=0.02), but was not significantly
associated with sample type (b=0.32 more potential sites in
PBMC compared to plasma; p=0.17). Glycosylation in V1V2
was increased in those with stage 3 (b=0.96, p=0.002), but not
stage 2 or 4 compared to stage 1 infection, and was decreased in
those with CD4 counts ,200 cells/ml (b=20.63, p=0.04
compared to CD4 counts .500). Similar findings were obtained
in an analysis restricted to sequences derived from plasma; the
number of PNLGS in V1V2 increased with calendar year of
sampling (b=0.05 increase per year; p=0.001), was increased in
those with stage 3 infection (b=1.14, p=0.001) and was
decreased in those with CD4 counts ,200 cells/ml (b=20.84,
p=0.04 compared to CD4 counts .500). However, in PBMC,
the number of sequences was limited, and no associations
between the number of potential glycosylation sites and clinical
features achieved statistical significance. Glycosylation in V4
decreased (p,0.001), while in V5 glycosylation increased with
calendar year (b=0.01 per year, p=0.02), although the
magnitude of these effects was small (b=20.03 per year, and
0.01 per year, respectively).
Coreceptor usage, clinical factors and V1V2 loop
length. (Also see Text S1 section S5 and Figures S10 and
S11.) We next used four published genotypic methods to infer
coreceptor usage based on V3 loop amino acid sequence [62–65].
In our dataset, 4476 V3 loop sequences were available for scoring,
and were derived from 129 individuals. 121 V3 loops could not be
scored by the PGRC method because the aligned sequences
exceeded the length limit specified by the input format (40
characters). There was agreement in coreceptor usage assignment
by all of the methods in 3644 of 4476 sequences (81.4%) and
disagreement between one or more methods in the remaining 832
sequences. 1046 of 4476 sequences were scored as CXR4-using or
syncytium-inducing by one or more methods, and the remaining
3430 were uniformly scored as CCR5 or non-syncytium by all
methods. 60 of 129 individuals had at least one X4-scoring V3
loop as determined by one or more of the prediction methods,
while the remaining 69 had only CCR5-scoring sequences.
We then considered inferred coreceptor usage as a function of
time since infection, clinical stage, CD4 counts, HIV viral load,
and V1V2 length, both overall and separately in plasma- and
PBMC–derived viruses. Because the PSSM method provides a
continuous numerical measure corresponding to the sequence
position on a continuum of the evolutionary changes leading to X4
usage (the PSSM score), we examined PSSM score in relation to
these variables. Overall, in separate GEE regression analyses,
PSSM score was not related to time since infection (p=0.9) or
HIV viral load (p=0.5). However, PSSM score was significantly
increased (indicating greater CXCR4 usage) in those with stage 4
(b=6.34, p=0.0002) but not stage 2 or stage 3 infection (p=0.8
each). Similarly, PSSM score was significantly increased in those
with intermediate (200–500 cells/ml) and low (,200 cells/ml)
CD4 counts (b=1.52, p=0.02 and b=6.62; p,0.0001, respec-
tively) compared to those with CD4 counts above 500 cells/ml.
PSSM score was weakly associated with increased V1V2 length
Table 3. Multivariable regression analysis of V1V2 length vs. clinical variables.
Time since infection (Model 1) Infection Stage (Model 2)
Factor All seqs Plasma PBMC All seqs Plasma PBMC
Time since infection 0.59 (0.85) 0.77 (,0.001) 0.56 (0.86)
Stage 1 Ref Ref Ref
Stage 2 0.09 (0.9) 0.08 (0.9) 0.00 (0.9)
Stage 3 6.25 (,0.001) 6.65 (,0.001) 3.66 (0.10)
Stage 4 3.54 (0.02) 2.95 (0.06) 8.01 (0.01)
Factor CD4 count (Model 3) Viral Load (Model 4)
CD4 level All seqs Plasma PBMC All seqs Plasma PBMC
.500 Ref Ref Ref
200-500 0.87 (0.5) 0.45 (0.7) 8.13 (0.03)
,200 20.19 (0.9) 20.70 (0.7) 6.77 (0.09)
VL log10 (continuous) 20.61 (0.14) 20.58 (0.2) 20.84 (0.15)
Beta coefficients for V1V2 Length vs. Time since Infection (Model 1), Stage of Infection (Model 2), CD4 counts (Model 3) or HIV Viral Load (Model 4). b values and p-values
(in parentheses) are shown. Results are stratified by sample type (Plasma vs. PBMC), adjusting for year of sample collection. Time since infection was missing for 5
sequences, stage of infection for 242 sequences, CD4 count for 113 sequences, and viral load for 290 sequences with measured V1V2 length. Ref = Reference group.
Analyses were performed for all sequences collectively as well as for sequences derived from plasma and PBMC considered separately.
doi:10.1371/journal.ppat.1001228.t003
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The analyses restricted to plasma samples yielded similar results,
with PSSM score strongly associated with stage 4 infection
(b=8.54, p,0.0001), intermediate (200–500 cells/ml) and low
(,200 cells/ml) CD4 counts (b=1.67, p=0.03 and b=8.83;
p,0.0001, respectively) compared to those with CD4 counts
above 500 cells/ml, and PSSM score weakly associated with
increased V1V2 length (b=0.07; p=0.12 per one amino acid
increase in V1V2 length). In sequences derived from PBMC
samples, PSSM score was not associated with stage of infection,
CD4 counts, HIV viral load, or V1V2 length. However, PSSM
score was inversely associated with time since infection (b=20.15;
p=0.01 per year).
Longitudinal analyses
In the longitudinal dataset, significant V1V2 length increases
between first and second timepoints were noted in 10 of 22
subjects, a significant V1V2 length decrease over time occurred in
one subject, and no significant V1V2 length changes over time
were seen in the remaining 11 subjects. These findings appeared to
vary by stage of infection (t-test p=0.03). In the 15 patients from
the L1 group (individuals not meeting AIDS criteria at any time
prior to final sampling), the mean increase of V1V2 length per
subjects was 1.69 amino acids per year, and 9 subjects experienced
significant V1V2 length increases over time (Figures 4 and 5). In
contrast, of the seven subjects in the L2 group (individuals
progressing to AIDS between first and final sample), the mean
V1V2 length decreased by an average of 0.10 amino acids per year,
with only one having a significant trend of increasing length, while
one individual showed a significant decrease in length (Figure 6).
The distribution of V1V2 length change (increase or decrease) by
group was therefore asymmetric (Fisher’s exact test, p=0.02),
reflecting a trend of increasing length in asymptomatic individuals
(group L1) and stable or decreasing length in individuals with AIDS
(group L2) (Table 4). Three subjects in group L1 had extensive
longitudinal sampling (Figure 5); in 1362 and Q23 [51], there was a
period of V1V2 length stability of approximately 2 years, followed
by increase through 4.5 years. V1V2 length increase over time was
also seen in CC1. In the case of CC1, a pseudotyped virus was
created using the gp120 coding region from the initial timepoint
from this individual in a HIV-1 NL4-3 background, and cultured in
vitro [54]. In contrast to the patterns observed in vivo, V1V2 length
and number of glycosylation sites both declined rapidly over 20
generations in vitro (p,0.001).
Discussion
We have systematically examined gp120 subregion length
variation, and the relationship between length polymorphism, N-
linked glycosylation sites, and clinical markers of disease
progression. Although V1V2, V4 and V5 all displayed remarkable
length heterogeneity, and V1V2, C3 and V4 were also quite
variable with respect to glycosylation, the most significant
associations between virological and clinical variables localized
to the V1V2 region. We found that V1V2 length and glycosylation
increased significantly over time during chronic infection, and
Figure 4. V1V2 loop lengths over time in group L1. Sequences from plasma are represented by diamonds and sequences from PBMC are
represented by circles. Significant slopes are indicated in bold. X-axis denotes years elapsed between sampling time points, but do not necessarily
indicate the total duration of infection. The first author of the report in which data were originally presented is indicated in the upper left-hand corner
of each graph. Group L1 subjects did not meet criteria for AIDS at any time prior to the final sample. Subjects reported by McDonald et al had
received AZT monotherapy at one or more times prior to sampling.
doi:10.1371/journal.ppat.1001228.g004
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infection was the most influential factor in determining V1V2
length. In addition, there was a modest but significant increase in
V1V2 length over the period from 1984–2004. V5 loop length was
highly variable, but tended to decrease slightly in length over the
course of infection.
In SIV infection, the number of PNLGS in gp120 increases over
time in vivo following inoculation of a cell-passaged strain [71]. In
one earlier study in humans, Bunnik et al noted expansion in
gp120 length followed by contraction over time in 4 of 5
individuals receiving antiretroviral therapy, and similar changes in
glycosylation in 3 subjects [72]. Others have noted a relationship
between early infection and reduced V1V2 length and glycosyl-
ation in subtypes C and A [19,45]. In contrast, a comparison of
early and chronic HIV-1 subtype B sequences from the HIV
sequence database failed to reveal any significant difference in
V1V2 length [19], suggesting that these effects may be subtype-
specific. Data on length/glycosylation changes during transmission
have been conflicting. Derdeyn et al [45] demonstrated reduced
length and glycosylation in V1–V4 following heterosexual
transmission in HIV-1 subtype C. However, Frost et al failed to
note similar findings in a study of eight subtype B homosexual
transmission pairs [47], and in our examination of these and 10
additional subtype B infected homosexual transmission pairs, we
found no consistent pattern of change in V1–V2 or V1–V4 length
or glycosylation upon transmission [46].
Interpretation of the data presented here may be affected by
several methodological factors. There is probably some variation
in the accuracy of the reported time of infection for sequences
obtained from previous reports. In some cases, sequences obtained
from prior publications may have been obtained under conditions
permitting template resampling [73], and a systematic error due to
evolving laboratory methods could result in bias. Also, in our
analyses, we have not formally corrected for multiple comparisons.
Physiological factors are also likely to introduce some noise,
particularly in cross-sectional analyses of parameters with respect
to time since infection. The individuals included here represent a
broad spectrum of clinical scenarios, diverse host immune
response profiles and varying disease progression rates. Plasma
sequences may receive contributions from both recently infected
target cells and older reservoirs, and therefore imperfectly reflect
selective pressures prevailing at the time of infection. Finally,
length and glycosylation phenotypes are likely to be affected by
chance events and unknown factors not considered in our
analyses. Therefore, the effects we describe are influential rather
than deterministic, and reflect important selective forces that can
be discerned against a background of high inter-individual
variation.
Despite these limitations, the analyses presented here and the
work of others [40,45–47,72] provide the outlines of an overall
pattern characterized by transmission of randomly selected V1V2
loop lengths from viruses present in the donor pool, a brief decline
in loop size during the initial months immediately following
infection, gradual selection for bulkier V1V2 loops during chronic
infection, and finally, reversion to more compact loops during late
stage illness. Structural studies [22,23], neutralization studies
[20,34–38,42], and in vitro data on viruses lacking V1 and V2
[43,44] suggest that one major function of the V1V2 region may
be to permit evasion from humoral immune responses in the host.
Thus, the trends outlined above support the hypothesis that HIV
populations may evolve to escape humoral selective pressure by
increasing V1V2 loop size. According to this view, the newly
infected, immunologically naı ¨ve host might be expected to harbor
relatively short V1V2 loops that eventually lengthen in response to
Figure 5. V1V2 length vs. time in subjects Q23, CC1 and 1362. Panel A: Subject Q23, infected with HIV subtype A. Sequences were derived
from PBMC (black circles), plasma (black diamonds) and DNA from cervical lymphocytes (green squares) as described by Poss et al [80]. Panel B:
Subject CC1, infected with subtype A. Sequences were obtained from plasma (black diamonds) and tissue culture (red squares). Length change of in
vitro sequences occurs over , 40 days, and are represented along an expanded X-axis for clarity.
doi:10.1371/journal.ppat.1001228.g005
Figure 6. V1V2 loop lengths over time in group L2. Sequences from plasma are represented by diamonds and sequences from PBMC are
represented by circles. Significant slopes are indicated in bold. X-axis denotes years elapsed between sampling time points, but do not necessarily
indicate the total duration of infection. The first author of the report in which data were originally presented are indicated in the upper left-hand
corner of each graph. Group L2 subjects were reported to have an AIDS-defining illness or peripheral CD4 count ,200/mm
3 between the first and
second samples.
doi:10.1371/journal.ppat.1001228.g006
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Experimental evidence indicating that relaxation of antibody-
mediated selective pressure during early infection is associated
with shorter loops is provided by Derdeyn, who demonstrated
significantly greater neutralization sensitivity among five recipients
during early infection, than in the corresponding donors [45]. The
decline in V1V2 size observed in advanced disease probably
reflects waning effectiveness of humoral immunity in hosts with
late-stage illness and profound immune dysregulation (Figure 7).
This decline is also congruent with previous findings of an inverse
relationship between the rate of HIV genetic evolution and the
rate of CD4 T cell decline in some individuals [74]. The dramatic
reduction in V1V2 length associated with transfer to the in vitro
environment [54] represents the extreme case of absent host
immunity, where viruses without an unnecessarily bulky V1V2
loop achieve maximum replicative fitness. As would be expected,
the patterns we observe are most pronounced in plasma sequences,
which most directly reflect the selective forces present at the time
of sampling. In contrast, a significant increase in V1V2 length over
time was not seen in the PBMC compartment. These observations
are consistent with the presence of archived genotypes from earlier
times during the course of infection within the PBMC compart-
ment. We also note that genotypes present in plasma may emanate
from other cellular compartments in addition to PBMC, and may
therefore reflect somewhat different evolutionary pressures.
However, a considerably greater number of V1V2 sequences
were derived from plasma, and sample size may also account for
some of the differences observed between these compartments.
Our model may help to explain a failure to find any significant
difference in V1V2 length in a comparison of early and chronic
HIV-1 subtype B sequences (including sequences from late-stage
individuals) [19]. When we reanalyzed the data presented by
Chohan [19] after separating subjects with stable chronic illness
from subjects with AIDS (Figure S13), we observed a pattern of
Table 4. Summary of longitudinal data.
ID Slope p-value Group
133 2.1774 ,.0001 L1
1362 0.7478 ,.0001 L1
153 0.6097 0.0016 L1
159 0.5801 0.0943 L1
27570 1.8929 0.0566 L1
27571 1.8123 ,.0001 L1
309 0.8926 ,.0001 L1
A 1.25 0.0575 L1
C 2.8704 ,.0001 L1
CC1 6.29 ,.0001 L1
E 0.2 0.8591 L1
G 2.6462 ,.0001 L1
I 0.7778 0.4324 L1
Q23 2.4755 ,.0001 L1
Q47 0.1087 0.808 L1
5007 20.1765 0.0856 L2
7340 20.0114 0.9655 L2
B 20.1333 0.0704 L2
D 0.1948 0.788 L2
F 24.1455 ,.0001 L2
H 1.0261 0.2487 L2
J 2.5611 0.0401 L2
Initial parameter estimates and p-values were used when only two time points
were available. When multiple timepoints were available, final GEE estimates
and p-values were used. P-values less than 0.05 are shown in bold.
doi:10.1371/journal.ppat.1001228.t004
Figure 7. Proposed evolution of V1V2 loop size change during transmission and HIV infection. At the time of sexual transmission, a
significant genetic bottleneck occurs in which one or a small number of donor variants is transmitted to the recipient, without clear selection for loop
size (represented on the y-axis). During early infection, prior to an effective host response, viral variants with a compact V1V2 loop have a competitive
advantage, and V1V2 loop size remains stable or regresses. During chronic asymptomatic infection, mean V1V2 length increases in response to
(humoral) immune selective pressure. As immune function wanes, V1V2 loop length gradually declines.
doi:10.1371/journal.ppat.1001228.g007
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reported here (See Text S1, section S7). Similarly, we may explain
discordant results obtained on V1V2 length variation during
transmission of HIV-1 subtypes C and B. While a trend towards
shorter loops in recipients was seen in subtype C [45] but not B
[46,47], it is likely for methodological reasons that the subjects
studied by Derdeyn were sampled at somewhat later times than
those of Frost and Liu. Thus the sequences in the latter two studies
would be expected to be a random sampling from the donor pool,
while those of Derdeyn might reflect the expected shortening prior
to the onset of an effective antibody response. Indeed, when we
examine a much larger set of subtype A and C transmission pairs
from East Africa with more precisely known sampling times
obtained soon after transmission, it is difficult to appreciate
any consistent pattern of V1V2 length change (See Text S1,
section S8 and Figure S14). Thus there may be no need to infer
separate mechanisms for different HIV-1 subtypes and modes of
transmission.
In addition, we may also explain a trend of increasing V1V2
length by calendar year. If shorter and less glycosylated V1V2
were always selected during transmission, transmission from
donors in early infection would maintain a constant V1V2 length
within the epidemic, whereas if all new cases were acquired from
chronically infected hosts, this increase of V1V2 length by
calendar year could be dramatic. However, most studies suggest
that about half of transmission events involve subjects in early
infection [46,75,76], consistent with the moderate trend we
observed. Alternatively, the temporal trends we have observed
could represent a gradual adaptation by HIV-1 to host the host
environment at the population level, a hypothesis that has been
proposed by several investigators with respect to mutational escape
from HLA-restricted CTL epitopes [77–79].
Finally, our results imply that the polymorphisms seen in V1V2
reflect the ability of the host to mount a meaningful immunological
response, rather than virologic features that dictate the course of
illness. That is, we argue that V1V2 length change is a
consequence of environmental selective pressure rather than a
causative factor in disease progression.
Supporting Information
Text S1 Supporting analyses text - PDF document containing
text containing supplementary analyses and citations.
Found at: doi:10.1371/journal.ppat.1001228.s001 (0.14 MB PDF)
Figure S1 V1V2 length vs. virologic and clinical parameters I.
Panel A: V1V2 length vs. log10 plasma viral load (no significant
relationship). Panel B: V1V2 length vs. peripheral CD4 T-cell
count (no significant relationship). Panel C: V1V2 length by
coreceptor usage. Box-plots depict minimum, 1
st quartile, median
(red line), 3
rd quartile and maximum values in each group, with
superimposed individual length measurements. In this series,
V1V2 sequences associated with V3 loops predicted to be X4-
tropic by PSSM are slightly longer compared with sequences
associated with R5-tropic V3 loops (median 71 vs. 66 amino acids,
p=3.49610
-5, MW test). However, a plot of V1V2 length vs.
PSSM score (Panel D) does not reveal a clear linear correlation
between V1V2 length and PSSM score.
Found at: doi:10.1371/journal.ppat.1001228.s002 (1.15 MB
TIF)
Figure S2 V1V2 length vs. virologic and clinical parameters II.
Panel A: V1V2 length vs. time since infection. As described
earlier, a significant positive correlation V1V2 length and time
since infection is evident (R=0.149) Panel B: V1V2 length by
stage of infection. Box-plots depict minimum, 1
st quartile, median
(red line), 3
rd quartile and maximum values in each stage group,
with superimposed individual length measurements. Highly
significant differences in V1V2 length are seen between stage 3
and stages 1,2 and 4 (p,2.2610
216, M-W rank sum test),
reflecting V1V2 lengthening in chronic illness, followed by
contraction in late disease. Panel C: V1V2 length by site (PBMC
vs. plasma). In this univariate comparison, there is no significant
length difference between V1V2 loops obtained from PBMC
(median 68 amino acids) and plasma (median 66 amino acids,
p=0.93). Panel D: V1V2 length vs. year of sampling. As
described, there is a significant positive correlation between V1V2
length and year of sampling.
Found at: doi:10.1371/journal.ppat.1001228.s003 (1.14 MB TIF)
Figure S3 V1V2 glycosylation vs. virological and clinical
parameters I. Panel A: Number of V1V2 glycosylation sites vs.
log10 plasma viral load (no significant relationship). Panel B:
Number of V1V2 glycosylation sites vs. peripheral CD4 T-cell
count (no clear correlation observed). Panel C: V1V2 glycosyl-
ation sites by inferred coreceptor usage (R5 or X4). Box-plots
report minimum, 1
st quartile, median (red line), 3
rd quartile and
maximum values in each stage group, with superimposed
individual measurements. No clear differences in glycosylation
are noted between V1V2 loops associated with R5-tropic and X4-
tropic V3 loops (median 6 and 6 PNLGS, respectively). Panel D:
Number of V1V2 glycosylation sites vs. PSSM score (no significant
relationship).
Found at: doi:10.1371/journal.ppat.1001228.s004 (1.07 MB TIF)
Figure S4 V1V2 glycosylation vs. virological and clinical
parameters II. Panel A: Number of V1V2 glycosylation sites vs.
time since infection. As with V1V2 length, in a univariate analysis
there is a modest but significant linear correlation between time
since infection and the extent of V1V2 glycosylation (b=0.12
amino acids/year, R
2=0.09). Panel B: Number of V1V2
glycosylation sites by clinical stage. Similar to what was observed
for V1V2 length, glycosylation in chronic illness (stage 3) was
significantly greater than in early and late disease (p,1610
28),
reflecting increasing glycosylation during chronic infection,
followed by a decline in the extent of glycosylation during AIDS.
Panel C: V1V2 glycosylation sites by site (PBMC or plasma).
Box-plots report minimum, 1
st quartile, median (red line), 3
rd
quartile and maximum values in each stage group, with
superimposed individual measurements. No clear differences in
glycosylation are noted between V1V2 loops obtained from
PBMC vs. plasma (median PNLGs 5 and 6, respectively, p=0.59).
Panel D: Number of V1V2 glycosylation sites vs. year of
sampling. There is a negligible positive correlation between V1V2
PNLG and year of sampling (b=0.05, R
2=0.06)
Found at: doi:10.1371/journal.ppat.1001228.s005 (1.13 MB TIF)
Figure S5 Resampling analysis: R
2 values for multiple linear
regression of V1V2 length on the independent variables time
since infection, year of sampling, and sample type for the entire
dataset (red squares h)a n df o r1 0 0p a r a l l e lr a n d o m l yr e s a m p l e d
datasets derived from the original dataset (green diamonds e).
Correlation coefficients obtained in the resampled datasets were
consistent with the correlation coefficient obtained using all
data.
Found at: doi:10.1371/journal.ppat.1001228.s006 (1.33 MB TIF)
Figure S6 V1V2 sequence length vs. time since infection -
sliding window analysis: Length measurements (red + sign) and R
2
values (blue triangles D) for univariate linear regression analyses of
datasets excluding 0.4-year periods since the time of infection. 0.4-
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each D datapoint. The correlation strength of the linear model is
greatest for datasets excluding the earliest two 0.4-year periods
(first two datapoints), indicating that linear regression of V1V2
length on time since infection most accurately explains data
obtained at times after approximately 0.8 years.
Found at: doi:10.1371/journal.ppat.1001228.s007 (1.07 MB TIF)
Figure S7 Subregion length (V1–V5) vs. time since infection for
the V1V5 region (purple circles), the V1V4 region (green
diamonds) and V1V2 (blue squares), V4 (red triangles) and V5
(orange diamonds) considered separately. A significant trend
towards increasing length seen in V1V2, V1V4 and V1V5 can
be ascribed primarily to changes in V1V2.
Found at: doi:10.1371/journal.ppat.1001228.s008 (2.13 MB TIF)
Figure S8 Subregion glycosylation (V1–V5) vs. time since
infection for the V1V5 region (purple circles), the V1V4 region
(green diamonds) and for V1V2 (blue squares) and V4 (red
triangles) considered separately. A modest trend towards increas-
ing glycosylaton seen in V1V2, V1V4 and V1V5 can be ascribed
primarily to changes in V1V2
Found at: doi:10.1371/journal.ppat.1001228.s009 (2.38 MB TIF)
Figure S9 Agreement between 4 bioinformatic coreceptors used
to assign probable coreceptor usage. There was complete
agreement between all methods for ,80% of sequences examined,
while in the remaining 20%, there was some disagreement in
assignment between one or more scoring methods. Most sequences
were predicted to be CCR5-tropic by all methods (white bar),
while a modest number of sequences was predicted to be CXCR4-
tropic by all methods. The remaining sequences were scored
differently by various methods, as represented (colored bars).
Found at: doi:10.1371/journal.ppat.1001228.s010 (2.84 MB
TIF)
Figure S10 V1V2 sequence length vs. time since infection and
PSSM score. Rising PSSM scores (color scale), depicted as warmer
colors, indicate a greater likelihood of CXCR4 coreceptor usage;
in this dataset, predicted X4 coreceptor usage occurs at a PSSM
score of approximately -2. In these data, there is a pronounced
preponderance of CCR5-using viruses, with a trend towards
increasing prevalence of X4-tropic viruses during chronic
infection. However, X4 and R5 viruses are distributed throughout
all infection times, and cannot be easily distinguished on the basis
of V1V2 length.
Found at: doi:10.1371/journal.ppat.1001228.s011 (1.15 MB TIF)
Figure S11 V1V2 potential N-linked glycosylation sites vs.
V1V2 length and PSSM score (color scale). There is a very
marked dependence of glycosylation on length (b=0.13 PNGL/
amino acid, R
2=0.52). X4-usage appears to be more commonly
associated with V1V2 sequences bearing 4-7 PNLG sites, than
with sequences with more than 7 sites (and see figure S1 panel D).
Found at: doi:10.1371/journal.ppat.1001228.s012 (1.10 MB TIF)
Figure S12 V1V2 and Stage of Illness. V1V2 length vs. Time
since Infection for stage 1 (orange ‘‘+’’), stage 2 (gray triangles),
stage 3 (blue squares), and stage 4 (red diamonds). There is a slight
decline in V1V2 length from stage 1 to stage 2, reflecting
regression from transmitted viruses of essentially random lengths
to shorter loop lengths during early infection prior to the onset of a
meaningful immune response. This is followed by a strong trend
towards lengthening during chronic infection (stage 3) and a
weakening of this trend in late-stage illness (stage 4).
Found at: doi:10.1371/journal.ppat.1001228.s013 (1.52 MB TIF)
Figure S13 Chohan Data revisited: V1V2 sequence length for
subjects in early infection (first bar), chronic infection and AIDS
considered together (second bar), chronic stable infection only
(third bar), and individuals with AIDS-defining clinical conditions
(fourth bar). Length differences between ‘‘early’’, ‘‘chronic’’ and
‘‘AIDS’’ are statistically significant (p#0.02). Thus, separation of
sequences obtained during AIDS from sequences obtained during
chronic stable infection reveals a trend of rising V1V2 length
through chronic infection, followed by falling length in AIDS that
is not otherwise apparent.
Found at: doi:10.1371/journal.ppat.1001228.s014 (1.04 MB TIF)
Figure S14 V1V2 length during transmission: Change in mean
loop length between donor and recipient in 44 transmission pairs
involving HIV-1 subtypes A, C and B, presented by Haaland,
Derdeyn, Frost and Liu. Panels A–C: Difference in mean loop
length between donors and recipients vs. time since infection for
V1V2 (panel A), C2–V4 (panel B), and V1–V4 (panel C).
Panel D:D i f f e r e n c ei nm e a nl o o pl e n g t hb e t w e e nd o n o r sa n d
recipientsvs.themeanlooplength(forthecorrespondingregion)inthe
donor.SubtypeAsequences(Haaland,representedbyred+),Subtype
B sequences (Frost, blue X) and Liu (blue squares) and subtype C
sequences (Haaland, green squares, and Derdeyn, green X).
Found at: doi:10.1371/journal.ppat.1001228.s015 (2.25 MB TIF)
Table S1 Published sequence data. Accession Numbers for
previously published sequences included in cross-sectional, longi-
tudinal and transmission analyses.
Found at: doi:10.1371/journal.ppat.1001228.s016 (0.05 MB PDF)
Table S2 Multivariable regression analysis of V1V2 length vs.
clinical variables, upper and lower 5% excluded. Beta coefficients
for V1V2 Length vs. Time since Infection (Model 1), Stage of
Infection (Model 2), CD4 counts (Model 3) or HIV Viral Load
(Model 4). b values and p-values (in parentheses) are shown.
Results are stratified by sample type (Plasma vs. PBMC), adjusting
for year of sample collection. Time since infection was missing for
5 sequences, stage of infection for 242 sequences, CD4 count for
113 sequences, and viral load for 290 sequences with measured
V1V2 length. Ref=Reference group. Analyses were performed
for all sequences collectively as well as for sequences derived from
plasma and PBMC considered separately. Sequences comprising
the upper and lower 5% by length were excluded from these
analyses.
Found at: doi:10.1371/journal.ppat.1001228.s017 (0.06 MB PDF)
Acknowledgments
We would like to thank Drs. Cynthia Derdeyn, Eric Hunter, Simon Frost,
Serena Spudich, Richard Price, Patrizia Bagnarelli and Eric Delwart for
their assistance and helpful discussions during the collection and analysis of
these data.
Author Contributions
Conceived and designed the experiments: MEC RZ. Performed the
experiments: MEC. Analyzed the data: MEC RZ SEH YL WD GSG TZ
JIM. Contributed reagents/materials/analysis tools: TZ JIM. Wrote the
paper: MEC RZ SEH YL WD GSG TZ JIM.
References
1. Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, et al. (1986)
Identification and characterization of conserved and variable regions in the
envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45: 637–
648.
HIV env Length Variation and Disease Progression
PLoS Pathogens | www.plospathogens.org 14 December 2010 | Volume 6 | Issue 12 | e10012282. Willey RL, Rutledge RA, Dias S, Folks T, Theodore T, et al. (1986)
Identification of conserved and divergent domains within the envelope gene of
the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci USA
83: 5038–5042.
3. Modrow S, Hahn BE, Shaw GM, Gallo RC, Wong-Staal F, et al. (1987)
Computer-assisted analysis of envelope protein sequences of seven human
immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved
and variable regions. J Virol 61: 570–578.
4. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV
evolution in early infection: selection pressures, patterns of insertion and
deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414.
5. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, et al. (1996) The
V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-
mediated blockade of infection [see comments]. Nat Med 2: 1244–1247.
6. Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor:
functional cDNA cloning of a seven-transmembrane, G protein-coupled
receptor. Science 272: 872–877.
7. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo IF, et al. (1997) Selective
employment of chemokine receptors as human immunodeficiency virus type 1
coreceptors determined by individual amino acids within the envelope V3 loop. J
Virol 71: 7136–7139.
8. Goudsmit J, Debouck C, Meloen RH, Smit L, Bakker M, et al. (1988) Human
immunodeficiency virus type 1 neutralization epitope with conserved architec-
ture elicits early type-specific antibodies in experimentally infected chimpanzees.
ProcNatlAcadSciUSA 85: 4478–4482.
9. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, et al. (1989)
Principal neutralizing domain of the human immunodeficiency virus type 1
envelope protein. ProcNatlAcadSciUSA 86: 6768–6772.
10. Luo L, Li Y, Chang JS, Cho SY, Kim TY, et al. (1998) Induction of V3-specific
cytotoxic T lymphocyte responses by HIV gag particles carrying multiple
immunodominant V3 epitopes of gp120. Virology 240: 316–325.
11. Watanabe N, McAdam SN, Boyson JE, Piekarczyk MS, Yasutomi Y, et al.
(1994) A simian immunodeficiency virus envelope V3 cytotoxic T-lymphocyte
epitope in rhesus monkeys and its restricting major histocompatibility complex
class I molecule Mamu-A*02. J Virol 68: 6690–6696.
12. Hartley O, Klasse PJ, Sattentau QJ, Moore JP (2005) V3: HIV’s switch-hitter.
AIDS Res Hum Retroviruses 21: 171–189.
13. Hill MD, Lorenzo E, Kumar A (2004) Changes in the human immunodeficiency
virus V3 region that correspond with disease progression: a meta-analysis. Virus
Res 106: 27–33.
14. Ida S, Gatanaga H, Shioda T, Nagai Y, Kobayashi N, et al. (1997) HIV type 1
V3 variation dynamics in vivo: Long-term persistence of non-syncytium-
inducing genotypes and transient presence of syncytium-inducing genotypes
during the course of progressive AIDS. AIDS Res and Human Retrovir 13:
1597–1609.
15. Palmer C, Balfe P, Fox D, May JC, Frederiksson R, et al. (1996) Functional
characterization of the V1V2 region of human immunodeficiency virus type 1.
Virology 220: 436–449.
16. Masciotra S, Owen SM, Rudolph D, Yang C, Wang B, et al. (2002) Temporal
relationship between V1V2 variation, macrophage replication, and coreceptor
adaptation during HIV-1 disease progression. Aids 16: 1887–1898.
17. Kitrinos KM, Hoffman NG, Nelson JA, Swanstrom R (2003) Turnover of env
variable region 1 and 2 genotypes in subjects with late-stage human
immunodeficiency virus type 1 infection. J Virol 77: 6811–6822.
18. Shioda T, Oka S, Xin X, Liu H, Harukuni R, et al. (1997) In vivo sequence
variability of human immunodeficiency virus type 1 envelope gp120: association
of V2 extension with slow disease progression. J Virol 71: 4871–4881.
19. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, et al. (2005) Selection for
human immunodeficiency virus type 1 envelope glycosylation variants with
shorter V1-V2 loop sequences occurs during transmission of certain genetic
subtypes and may impact viral RNA levels. J Virol 79: 6528–6531.
20. Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus
type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over
the course of infection, and these modifications affect antibody neutralization
sensitivity. J Virol 80: 9586–9598.
21. Chackerian B, Rudensey LM, Overbaugh J (1997) Specific N-linked and O-
linked glycosylation modifications in the envelope V1 domain of simian
immunodeficiency virus variants that evolve in the host alter recognition by
neutralizing antibodies. J Virol 71: 7719–7727.
22. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure
of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a
neutralizing human antibody. Nature 393: 648–659.
23. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, et al. (2005) Determining
the structure of an unliganded and fully glycosylated SIV gp120 envelope
glycoprotein. Structure 13: 197–211.
24. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH (2005) Chemokine
receptors in the central nervous system: role in brain inflammation and
neurodegenerative diseases. Brain Res Brain Res Rev 48: 16–42.
25. Andeweg A, Leeflang P, Osterhaus A, Bosch M (1993) Both the V2 and V3
regions of the human immunodeficiency virus type 1 surface glycoprotein
functionally interact with other envelope regions in syncytium formation. J Virol
67: 3232–3239.
26. Groenink M, Fouchier RAM, Broersen S, Baker CH, Koot M, et al. (1993)
Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science
260: 1513–1516.
27. Koito A, Harrowe G, Levy JA, Cheng-Mayer C (1994) Functional role of the
V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein
gp120 in infection of primary macrophages and soluble CD4 neutralization. J
Virol 68: 2253–2259.
28. O’Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, et al. (1990) HIV-1
tropism for mononuclear phagocytes can be determined by regions of gp120
outside the CD4-binding domain. Nature 348: 69–73.
29. Sullivan N, Thali M, Furman C, Ho DD, Sodroski J (1993) Effect of amino acid
changes in the V1/V2 region of the human immunodeficiency virus type 1
gp120 glycoprotein on subunit association, syncytium formation, and recogni-
tion by a neutralizing antibody. J Virol 67: 3674–3679.
30. Westervelt P, Trowbridge DB, Epstein LG, Blumberg BM, Li Y, et al. (1992)
Macrophage tropism determinants of human immunodeficiency virus type 1 in
vivo. J Virol 66: 2577–2582.
31. Toohey K, Wehrly K, Nishio J, Perryman S, Chesebro B (1995) Human
immunodeficiency virus envelope V1 and V2 regions influence replication
efficiency in macrophages by affecting virus spread. Virology 213: 70–79.
32. Wang N, Zhu T, Ho DD (1995) Sequence diversity of V1 and V2 domains of
gp120 from human immunodeficiency virus type 1: lack of correlation with viral
phenotype. J Virol 69: 2708–2715.
33. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, et al. (2006) Human
immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness
mutations compensate for V3 loss-of-fitness mutations. J Virol 80: 750–758.
34. Benichou S, Legrand R, Nakagawa N, Faure T, Traincard F, et al. (1992)
Identification of a neutralizing domain in the external envelope glycoprotein of
simian immunodeficiency virus. AIDS Res Hum Retroviruses 8: 1165–1170.
35. Kent KA, Rud E, Corcoran T, Powell C, Thiriart C, et al. (1992) Identification
of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency
virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses 8:
1147–1151.
36. Matsumi S, Matsushita S, Yoshimura K, Javaherian K, Takatsuki K (1995)
Neutralizing monoclonal antibody against a external envelope glycoprotein
(gp110) of SIVmac251. AIDS Res Hum Retroviruses 11: 501–508.
37. Jurkiewicz E, Hunsmann G, Schaffner J, Nisslein T, Luke W, et al. (1997)
Identification of the V1 region as a linear neutralizing epitope of the simian
immunodeficiency virus SIVmac envelope glycoprotein. J Virol 71: 9475–9481.
38. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, et al. (2004) The V1/
V2 domain of gp120 is a global regulator of the sensitivity of primary human
immunodeficiency virus type 1 isolates to neutralization by antibodies commonly
induced upon infection. J Virol 78: 5205–5215.
39. Lamers S, Sleasman JW, She JX, Barrie KA, Pomeroy SM, et al. (1993)
Independent variation and positive selection in env V1-V2 domains within
maternal-infant strains of human immunodeficiency virus type-1 in vivo. JVirol
67: 3951–3960.
40. Rybarczyk BJ, Montefiori D, Johnson PR, West A, Johnston RE, et al. (2004)
Correlation between env V1/V2 region diversification and neutralizing
antibodies during primary infection by simian immunodeficiency virus sm in
rhesus macaques. J Virol 78: 3561–3571.
41. Frost SD, Wrin T, Smith DM, Pond SL, Liu Y, et al. (2005) Neutralizing
antibody responses drive the evolution of human immunodeficiency virus type 1
envelope during recent HIV infection. Proc Natl Acad Sci U S A 102:
18514–18519.
42. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, et al. (2006) Evidence
for potent autologous neutralizing antibody titers and compact envelopes in
early infection with subtype C human immunodeficiency virus type 1. J Virol 80:
5211–5218.
43. Johnson WE, Morgan J, Reitter J, Puffer BA, Czajak S, et al. (2002) A
replication-competent, neutralization-sensitive variant of simian immunodefi-
ciency virus lacking 100 amino acids of envelope. J Virol 76: 2075–2086.
44. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, et al. (1997) Replication
and neutralization of human immunodeficiency virus type 1 lacking the V1 and
V2 variable loops of the gp120 envelope glycoprotein. J Virol 71: 9808–9812.
45. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004)
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual trans-
mission. Science 303: 2019–2022.
46. Liu Y, Curlin ME, Diem K, Zhao H, Ghosh AK, et al. (2008) Env length and N-
linked glycosylation following transmission of human immunodeficiency virus
Type 1 subtype B viruses. Virology 374: 229–233.
47. Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, et al. (2005) Characterization of
human immunodeficiency virus type 1 (HIV-1) envelope variation and
neutralizing antibody responses during transmission of HIV-1 subtype B. J
Virol 79: 6523–6527.
48. Hughes ES, Bell JE, Simmonds P (1997) Investigation of population diversity of
human immunodeficiency virus type 1 in vivo by nucleotide sequencing and
length polymorphism analysis of the V1/V2 hypervariable region of env. J Gen
Virol 78((Pt 11)): 2871–2882.
49. Schacker T, Collier AC, Hughes J, Shea T, Corey L (1996) Clinical and
epidemiologic features of primary HIV infection. Ann Intern Med 125:
257–264.
HIV env Length Variation and Disease Progression
PLoS Pathogens | www.plospathogens.org 15 December 2010 | Volume 6 | Issue 12 | e100122850. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, et al. (1987) The
Multicenter AIDS Cohort Study: rationale, organization, and selected
characteristics of the participants. Am J Epidemiol 126: 310–318.
51. Poss M, Rodrigo AG, Gosink JJ, Learn GH, de Vange Panteleeff D, et al. (1998)
Evolution of envelope sequences from the genital tract and peripheral blood of
women infected with clade A human immunodeficiency virus type 1. J Virol 72:
8240–8251.
52. Dacheux L, Moreau A, Ataman-Onal Y, Biron F, Verrier B, et al. (2004)
Evolutionary dynamics of the glycan shield of the human immunodeficiency
virus envelope during natural infection and implications for exposure of the
2G12 epitope. J Virol 78: 12625–12637.
53. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, et al. (2006) Selection on the
human immunodeficiency virus type 1 proteome following primary infection. J
Virol 80: 9519–9529.
54. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, et al. (2002) HIV-1
escape from a small molecule, CCR5-specific entry inhibitor does not involve
CXCR4 use. Proc Natl Acad Sci U S A 99: 395–400.
55. McDonald RA, Mayers DL, Chung RC, Wagner KF, Ratto-Kim S, et al. (1997)
Evolution of human immunodeficiency virus type 1 env sequence variation in
patients with diverse rates of disease progression and T-cell function. J Virol 71:
1871–1879.
56. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al.
(1999) Consistent viral evolutionary changes associated with the progression of
human immunodeficiency virus type 1 infection. J Virol 73: 10489–10502.
57. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, et al. (2005) Evidence
that low-level viremias during effective highly active antiretroviral therapy result
from two processes: expression of archival virus and replication of virus. J Virol
79: 9625–9634.
58. Rodrigo AG, Goracke PC, Rowhanian K, Mullins JI (1997) Quantitation of
target molecules from polymerase chain reaction-based limiting dilution assays.
AIDS Res and Hum Retrovir 13: 737–742.
59. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, et al.
(2001) Cellular immune responses and viral diversity in individuals treated
during acute and early HIV-1 infection. J Exp Med 193: 169–180.
60. Delwart EL, Herring B, Rodrigo AG, Mullins JI (1995) Genetic Subtyping of
Human Immunodeficiency Virus Using a Heteroduplex Mobility Assay. PCR
Methods and Applications 4: S202–216.
61. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through sequence
weighting, position-specific gap penalties and weight matrix choice. Nucleic
Acids Res 22: 4673–4680.
62. Jensen MA, Li FS, van ’t Wout AB, Nickle DC, Shriner D, et al. (2003)
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4
transition by motif analysis of human immunodeficiency virus type 1 env V3
loop sequences. J Virol 77: 13376–13388.
63. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R (2007) Bioinformatics
prediction of HIV coreceptor usage. Nat Biotechnol 25: 1407–1410.
64. Pillai S, Good B, Richman D, Corbeil J (2003) A new perspective on V3
phenotype prediction. AIDS Res Hum Retroviruses 19: 145–149.
65. Boisvert S, Marchand M, Laviolette F, Corbeil J (2008) HIV-1 coreceptor usage
prediction without multiple alignments: an application of string kernels.
Retrovirology 5: 110.
66. Busch MP, Satten GA (1997) Time course of viremia and antibody
seroconversion following human immunodeficiency virus exposure. Am J Med
102: 117–124; discussion 125–116.
67. Constantine NT, van der Groen G, Belsey EM, Tamashiro H (1994) Sensitivity
of HIV-antibody assays determined by seroconversion panels. Aids 8:
1715–1720.
68. Hanley JA, Negassa A, Edwardes MD, Forrester JE (2003) Statistical analysis of
correlated data using generalized estimating equations: an orientation. Am J
Epidemiol 157: 364–375.
69. Burton P, Gurrin L, Sly P (1998) Extending the simple linear regression model to
account for correlated responses: an introduction to generalized estimating
equations and multi-level mixed modelling. Stat Med 17: 1261–1291.
70. Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and
continuous outcomes. Biometrics 42: 121–130.
71. Edmonson P, Murphey-Corb M, Martin LN, Delahunty C, Heeney J, et al.
(1998) Evolution of a Simian Immunodeficiency Virus pathogen. J Virol 72:
405–414.
72. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H (2008) Autologous
neutralizing humoral immunity and evolution of the viral envelope in the course
of subtype B human immunodeficiency virus type 1 infection. J Virol 82:
7932–7941.
73. Liu SL, Rodrigo AG, Shankarappa R, Learn GH, Hsu L, et al. (1996) HIV
quasispecies and resampling. Science 273: 415–416.
74. Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, et al. (1997)
Slower evolution of human immunodeficiency virus type 1 quasispecies during
progression to AIDS. J Virol 71: 7498–7508.
75. Pilcher CD, Tien HC, Eron JJ, Jr., Vernazza PL, Leu SY, et al. (2004) Brief but
Efficient: Acute HIV Infection and the Sexual Transmission of HIV. J Infect Dis
189: 1785–1792.
76. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, et al. (2005) Rates
of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai,
Uganda. J Infect Dis 191: 1403–1409.
77. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, et al. (2009)
Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458: 641–645.
78. Moore CB, John M, James IR, Christiansen FT, Witt CS, et al. (2002) Evidence
of HIV-1 adaptation to HLA-restricted immune responses at a population level.
Science 296: 1439–1443.
79. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, et al. (2002) Clustering
patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus
type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global
variation. J Virol 76: 8757–8768.
80. Poss M, Martin HL, Kreiss JK, Granville L, Chohan B, et al. (1995) Diversity in
virus populations from genital secretions and peripheral blood from women
recently infected with human immunodeficiency virus type 1. J Virol 69:
8118–8122.
HIV env Length Variation and Disease Progression
PLoS Pathogens | www.plospathogens.org 16 December 2010 | Volume 6 | Issue 12 | e1001228